CMPS COMPASS Pathways plc: Forward P/S Multiple

COMPASS Pathways plc (CMPS) is protected by exclusive patents for synthetic psilocybin while operating under strict FDA oversight. Demand for its innovative depression therapy remains stable and independent of market cycles. The forward P/S ratio based on forecasts reflects analyst expectations, where the value of characterizes this level, confirming the company's status as the primary scientific pioneer in psychedelic medicine.

CMPS COMPASS Pathways: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/13/2026

Financial and market metric breakdowns for COMPASS Corp (CMPS)

- market price and analyst price targets:

Price Chart COMPASS Pathways|CMPS - Average Forecast Price

- company stock capitalization data:

Market Capitalization COMPASS Corp|CMPS - Real Price to Acquire Entire Company

- issuer book value statistics:

Net Assets per Single Share COMPASS Pathways|CMPS - Total Stockholders' Equity|Market Value to Book Value Ratio compasspathways.com|CMPS - Cumulative Company Assets

- debt level and financial liquidity data:

- business earnings and investment ratios data:

CMPS - Final Profit|Expected Profit COMPASS Pathways plc|CMPS - Market Cap to Net Income|Forward P/E Multiple Compass Pathways|CMPS - PEG Multiple|Enterprise Value to EBITDA Ratio COMPASS Corp|CMPS - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) COMPASS Pathways|CMPS - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months compasspathways.com|CMPS - Net earnings per share growth this year|Earnings growth forecast for next year COMPASS Pathways plc

- revenue and sales details:

CMPS - Revenue and Sales Volume|Company Future Sales Volume COMPASS Pathways|CMPS - Price to Sales|Price-to-Projected Revenue Ratio COMPASS Corp

Fundamental company analysis:CMPS (COMPASS Pathways)

The forward P/S ratio reflects the business value relative to expected sales, allowing for the determination of the premium paid for future cash flows during periods of high volatility. Analysis of this forward revenue multiple helps assess market expectations for the commercialization of synthetic psilocybin by comparing the current capitalization of COMPASS Pathways plc (CMPS) with the potential implementation of revolutionary therapy methods for treatment-resistant depression.

Analysis of competing companies

Price-to-Projected Revenue Ratio Alkermes ALKS|Avadel Pharmaceuticals PLC (AVDL) - Market Cap to Future Revenue Ratio|atai Life Sciences Corp - Forward P/S Multiple|GH Research Group (GHRS) - Forward Price-to-Revenue Multiple|Mind Medicine (MNMD) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio lbpharma.us (LBRX)|Price-to-Projected Revenue Ratio Bright Minds Biosciences Inc.|Forward Price-to-Revenue Multiple Vanda Pharma (VNDA)|Price-to-Projected Revenue Ratio Cybin Inc. (CYBN)|ANRO: Future Price to Revenue|Forward P/S Multiple NRXP (NRx Pharmaceuticals)|Forward P/S Multiple Cingulate Inc CING|SILO - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio China Pharma Holdings CPHI|Clearmind Medicine (CMND) - Price-to-Projected Revenue Ratio|PBM - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple SPRC|SEEL: Forward Price to Sales|Price-to-Projected Revenue Ratio Virpax Pharmaceuticals (VRPX)|KRTX: Future Price to Revenue